Bioconjugate Insights presents a preview of the 5th Novel Conjugates Summit, taking place March 17–19, 2026, in Boston, MA, USA. The meeting will bring together discovery and early development leaders from biotech, pharma, and academia to examine how novel targeting formats and payload strategies are expanding the therapeutic reach of conjugates across oncology and beyond. With growing interest in bispecific ADCs (BsADCs), multispecific constructs, degraders, and immune-stimulating payloads, the summit will focus on how advances in targeting logic, delivery mechanisms, and payload design are helping developers address tumor heterogeneity, resistance, and on-target off-tissue toxicity. Across 3 days, the program will explore how emerging conjugate modalities are progressing from concept to preclinical and translational validation.
none listed (Wed,) studied this question.